Pricing and reimbursement conditions can also influence pharmaceutical performance as governments, healthcare systems, and insurers assess treatment costs and clinical value. Patent expirations create ...

No large pharma company has traversed this decade's ups and downs quite like Pfizer. As the company rolls ahead with a large restructuring campaign, some staffers in Ireland will soon feel the effects ...

Pfizer (NYSE:PFE) news as US markets steady near records ahead of July CPI, with the drugmaker's pharmaceutical operations and healthcare stocks in focus.

What began as a grassroots initiative has become embedded across Pfizer's research and manufacturing operations, helping reshape processes for Viagra and Paxlovid ...

Pfizer will reduce its costs by $2.5 billion in another round of cutbacks, which will kick in next year and run through 2029. The New York company unveiled the plan in its second-quarter earnings ...

Pharmaceutical giant Pfizer is preparing to eliminate more than 100 positions at its facility in Ireland this year. The multinational drug company is headquartered in Manhattan, New York City, and ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Albert Bourla, Pfizer's CEO, said on Monday that the company may move overseas drug manufacturing back ...

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and research ...

European Commission grants marketing authorization for Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine for the 2026-2027 season in the EU. Approval covers use in individuals aged 6 months and older ...

The drugmaker posted adjusted earnings of 77 cents per share and now expects full-year revenue of $60.5 billion to $62.5 ...